PF4-dependent disorders encompass a heterogeneous group of immune-mediated thrombotic syndromes, including heparin-induced thrombocytopenia (HIT), its autoimmune variants such as spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia (VITT). The recent identification of VITT and VITT-like entities has significantly expanded the diagnostic spectrum, complicating the retrospective interpretation of cases that occurred before their formal recognition. We report the case of a young patient who initially presented with a clinical and biological presentation suggestive of atypical HIT, at a time when neither spontaneous HIT nor VITT were defined. The patient was re-evaluated during the COVID-19 vaccination campaign, prompting a reassessment of the initial diagnosis in light of current knowledge on PF4-related disorders, which continue to increase in both diversity and complexity. A critical review of clinical and laboratory findings now favors a diagnosis of VITT-like syndrome over spontaneous HIT, although confirmatory testing is no longer feasible given the time elapsed since the acute phase. This case highlights the importance of revisiting historical cases using updated diagnostic criteria to improve the identification and management of these emerging and underrecognized syndromes.
Background: This case report investigates the effects of sotorasib treatment in a patient with acquired von Willebrand syndrome (AVWS) associated with monoclonal gammopathy of undetermined significance (MGUS), who subsequently developed non-small-cell lung carcinoma (NSCLC) with a KRAS G12C mutation. Case Presentation: The patient, a 79-year-old male, presented with a prolonged history of recurrent lower gastrointestinal bleeding attributed to digestive angiodysplasia, which had persisted for over 30 years. AVWS was suspected based on a qualitative deficiency in von Willebrand factor (VWF), with abnormal results for factor VIII activity (FVIII:C), VWF antigen (VWF:Ag), and VWF ristocetin cofactor activity (VWF:Rco) (40%, 20%, and <2.4%, respectively). Further evaluation revealed the presence of an IgM kappa monoclonal spike, suggesting MGUS. In 2022, the patient was diagnosed with NSCLC harboring the KRAS G12C mutation and initiated second-line treatment with sotorasib. Notably, one year after the initiation of sotorasib therapy, the patient’s hemostasis had normalized, accompanied by significant improvements in VWF levels. VWF multimer electrophoresis demonstrated the restoration of high-molecular-weight multimers (HMWMs), and serum protein electrophoresis no longer detected MGUS. Conclusion: These improvements were likely attributable to the indirect effects of sotorasib on the bone marrow microenvironment. By inhibiting KRAS in stromal cells and osteoclasts, sotorasib may have disrupted the supportive niche necessary for malignant plasma cell survival, resulting in a reduction in the monoclonal spike. Unfortunately, the patient eventually succumbed to carcinogenic pleurisy.